Recent advances in protein tyrosine phosphatase 1B inhibitors

Bibliography

• SALTIEL AR, KAHN CR: Insulin signaling and the regulation of glucose and lipid metabolism. Nature (2001) 414:799–806.
   PubMed Web of Science ®Google Scholar
• RAMACHANDRAN C, KENNEDY BP: Protein tyrosine phosphatase 1B: a novel target for type II diabetes and obesity. Curr. Top. Med. Chem. (2003) 3:749–757.
   PubMed Web of Science ®Google Scholar
• BANDYOPADHYAY D, KUSARI A, KENNER KA et al.: Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J. Biol. Chem. (1997) 272:1639–1645.
   PubMed Web of Science ®Google Scholar
• SEELY BL, STAUBS PA, REICHART DR et al.: Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes (1996) 45:1379–1385.
   PubMed Web of Science ®Google Scholar
• KENNER KA, ANYANWU E, OLEFSKY JM, KUSARI J: Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J. Biol. Chem. (1996) 271:19810–19816.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN BJ, BITTNER-KOWALCZYK A, WHITE MF, HARBECK M: Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adapter protein. J. Biol. Chem. (2000) 275:4283–4289.
   Google Scholar
• CALERA MR, VALLEGA G, PILCH PF: Dynamics of protein-tyrosine phosphatases in rat adipocytes. J. Biol. Chem. (2000) 275:6308–6312.
   PubMed Web of Science ®Google Scholar
• BYON JC, KUSARI AB, KUSARI J: Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell Biochem. (1998) 182:101–108.
   PubMed Web of Science ®Google Scholar
• AHMAD F, GOLDSTEIN BJ: Increasedabundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism. (1995) 44:1175–1184.
   PubMed Web of Science ®Google Scholar
• KUSARI J, KENNER KA, SUH KI, HILL DE, HENRY RR: Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. j Clin. Invest. (1994) 93:1156–1162.
   PubMed Web of Science ®Google Scholar
• MCGUIRE MC, FIELDS RM, NYOMBA BL et al.: Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans. Diabetes (1991) 40:939–942.
   PubMed Web of Science ®Google Scholar
• KENNER KA, HILL DE, OLEFSKY JM,KUSARI J: Regulation of protein tyrosine phosphatases by insulin and insulin-like growth Factor I. J. Biol. Chem. (1993) 268:25455–25462.
   PubMed Web of Science ®Google Scholar
• ELCHEBLY M, PAYETTE P, MICHALISZYN E et al.: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science (1999) 283:1544–1548.
   PubMed Web of Science ®Google Scholar
• ••The seminal study on PTP1B-knockoutmice. This work provides the most compelling evidence supporting PTP1B as a downregulator of insulin signalling and the development of PTP1B inhibitors as therapeutics for treating Type 2 diabetes and obesity.
   Google Scholar
• KLAIVIAN LD, BOSS 0, PERONI OD et al.: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. (2000) 20:5479–5489.
   Google Scholar
• ••An independent PTP1B knockout-mousestudy that confirms the results of Elchebly et[13]. These workers also report thattheir knockout mice exhibited an increase in metabolic rate and oxygen consumption, which may explain their resistance to diet-induced obesity. However, authors of the earlier study [13] have recently reported that no difference in oxygen consumption was observed in their knockout mice [2]. They suggest that expressing oxygen consumption as 02/ min/kg, as in [14], does not accurately reflect the measure of metabolic rate because it includes the metabolic inactive fat [2].
   Google Scholar
• ZABEAU L, LAVENS D, PEELMAN F, EYCKERMAN S, VANDEKERCKHOVE J, TAVERNIER J: The ins and outs of leptin receptor activation. FEBS Lett. (2003) 546:45–50.
   PubMed Web of Science ®Google Scholar
• ZABOLOTNY JM, BENCE-HANULEC KK, STRICKER-KRONGRAD A et al.: PTP1B regulates leptin signal transduction in vivo. Dev. Cell. (2002) 2:489–495.
   PubMed Web of Science ®Google Scholar
• ••This paper, along with [17], providescompelling evidence that PTP1B dephosphorylates Jak-2 and negatively regulates leptin signalling.
   Google Scholar
• CHENG A, UETANI N, SIMONCIC PD et al.: Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell. (2002) 2:497–503.
   PubMed Web of Science ®Google Scholar
• ••See [16].
   Google Scholar
• DI GUGLIELMO GM, DRAKE PG, BAASS PC, AUTHIER F, POSNER BI, BERGERON JJ: Insulin receptor internalization and signaling. Mol. Cell. Biochem. (1998) 182:59–63.
   PubMed Web of Science ®Google Scholar
• HAJ FG, MARKOVA B, KLAMAN LD, BOHMER FD, NEEL BG: Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J. Biol. Chem. (2003) 278:739–744.
   PubMed Web of Science ®Google Scholar
• HAJ FG, VERVEER PJ, SQUIRE A, NEEL BG, BASTIAENS PI: Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science (2002) 295: 1708-1711.
   Google Scholar
• BOUTE N, BOUBEKEUR S, LACASA D, ISSAD T: Dynamics of the interaction between the insulin receptor and protein tyrosine-phosphatase 1B in living cells. EMBO Rep. (2003) 4:313–319.
   PubMed Web of Science ®Google Scholar
• BARFORD D, FLINT AJ, TONKS NK: Crystal structure of human protein tyrosine phosphatase 1B. Science (1994) 263:1397–1404.
   PubMed Web of Science ®Google Scholar
• TONKS NK: PTP1B: from the sidelines to the front lines! FEBS Lett. (2003) 546:140–148.
   Google Scholar
• •A recent review on the key advances in the characterisation of the structure, regulation and function of PTP1B, and illustrates how the understanding of the properties of this enzyme has revealed principles that apply to the PTP family as a whole.
   Google Scholar
• WANG W-Q, SUN J-P, ZHANG Z-Y: An overview of the protein tyrosine phosphatase superfamily. Curr. Top. Med. Chem. (2003) 3:739–748.
   PubMed Web of Science ®Google Scholar
• ZHANG Z-Y: Protein tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis. Curr. Rev. Biochem. Mol. Biol. (1998) 33:1–52.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the structures and mechanisms of PTPs including PTP1B.
   Google Scholar
• JAI Z, BARFORD D, FLINT J, TONKS NK: Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science (1995) 268: 1754-1758.
   Google Scholar
• •The X-ray crystal structure of a catalytically inactive Cys215Ser PTP1B mutant complexed with a phosphotyrosine-bearing peptide.
   Google Scholar
• ZHANG ZY, MACLEAN D, McNAMARA D, SAWYER TK, DIXON JE: Protein tyrosine phosphatase substrate specificity: size and phosphotyrosine positioning requirements in peptide substrates. Biochemist?), (1994) 33:2285–2290.
   PubMed Web of Science ®Google Scholar
• HARLEY EA, LEVENS N: Protein tyrosinephosphatase 1B inhibitors for the treatment of Type 2 diabetes and obesity: recent advances. Curr. Opin. Investig Drug. (2003) 4:1179–1189.
   PubMedGoogle Scholar
• LIU, G: Protein tyrosine phosphatase 1B inhibition: opportunities and challenges. Curr. Med. Chem. (2003) 10:1407–1421.
   PubMed Web of Science ®Google Scholar
• TAYLOR SD: Inhibitors of protein tyrosine phosphatase 1B (PTP1B). Curr. Top. Med. Chem. (2003) 3:759–782.
   PubMed Web of Science ®Google Scholar
• •An extensive review on PTP1B inhibitors covering the primary scientific literature from the days of early development up to September 2002.
   Google Scholar
• ZHANG ZY, LEE SY: PTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity. Expert Opin. Investig. Drug. (2003) 12:223–233.
   PubMed Web of Science ®Google Scholar
• VAN HUIJSDUIJNEN RH, BOMBRUN A, SWINNEN D: Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today (2002) 7:1013–1019.
   PubMed Web of Science ®Google Scholar
• BLASKOVITCH MA, KIM H-0: Recent advances in the discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin. Ther. Patents (2002) 12:871–905.
   Web of Science ®Google Scholar
• •An extensive review on PTP inhibitors covering the primary scientific and patent literature from the days of early development up to early 2002.
   Google Scholar
• TOBIN JF, TAM S: Recent advances in thedevelopment of small molecule inhibitors of PTP1B for the treatment of insulin resistance and Type 2 diabetes. Curr. Opin. Drug. Discov. Devel. (2002) 5:500–512.
   PubMed Web of Science ®Google Scholar
• JOHNSON TO, ERMOLIEFF J, JIROUSEK MR: Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. (2002) 9:696–709.
   Google Scholar
• ZHANG, Z-Y: Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Ann. Rev. Pharmacol. Toxicol. (2002) 42:209–234.
   PubMed Web of Science ®Google Scholar
• UKKOLA 0, SANTANIEMI M: Protein tyrosine phosphataselB: A new target for the treatment of obesity and associated co-morbidities. J. Internal Med. (2002) 251:467–475.
   Google Scholar
• GOLDSTEIN BJ: Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for Type 2 diabetes mellitus, obesity and related states of insulin resistance. Curr. Drug Targets Immune. Endocr. Metabol. Disord. (2001) 1:265–275.
   PubMedGoogle Scholar
• ZHANG Z-Y: Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol. (2001) 5:416–423.
   PubMed Web of Science ®Google Scholar
• BURKE TR, YAO Z-J, LIU D-G, VOIGHT J, GAO Y: Phosphotyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers (2001) 60:32–44.
   PubMed Web of Science ®Google Scholar
• PUIUS YA, ZHAO Y, SULLIVAN M, LAWRENCE DS, ALMO SC, ZHANG ZY: Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc. Natl. Acad. Sci. USA (1997) 94:13420–13425.
   PubMed Web of Science ®Google Scholar
• •The first report describing the non-catalytic phosphate-binding site (site 2) in PTP1B.
   Google Scholar
• SALMEEN A, ANDERSON JN, MYERS MP, TONKS NK, BARFORD D: Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. MoL Cell, (2000) 6:1401–1412.
   PubMed Web of Science ®Google Scholar
• •X-ray crystal structure of a multi Tyr-P-bearing peptide binding to both the catalytic (site 1) and non-catalytic (site 2) sites in a C215A PTP1B mutant.
   Google Scholar
• BURKE TR, KOLE HK, ROLLER PP: Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem. Biophys. Res. Commun. (1994) 204:129–134.
   PubMed Web of Science ®Google Scholar
• •The first report describing the use of F2Pmp as a Tyr-P mimic.
   Google Scholar
• CHEN L, WU L, OTAKA A et cll.: Why isphosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem. Biophys. Res. Comm. (1995) 216:976–984.
   Google Scholar
• DESMARAIS S, FRIESEN RW, ZAMBONI R, RAMACHANDRAN C: [Difluro(phosphono)methyflphenylalanine-containing peptide inhibitors of protein tyrosine phosphatases. Biochem. J. (1999) 337:219–223.
   PubMed Web of Science ®Google Scholar
• ASANTE-APPIAH E, BALL K, SKOREY K et al.: The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein tyrosine phosphatase. j Biol. Chem. (2001) 276:26036–26043.
   PubMed Web of Science ®Google Scholar
• SKOREY K, KENNEDY BP, FRIESEN R, RAMACHANDRA C: Development of a robust scintillation assay for protein tyrosine phosphatase 1B using the catalytically inactive (C2155) mutant. Anal. Biochem. (2001) 291:269–278.
   PubMed Web of Science ®Google Scholar
• ASANTE-APPIAH E, PATEL S, DUFRESNE C et al.: The structure of PTP1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry (2002) 41:9043–9051.
   PubMed Web of Science ®Google Scholar
• DUFRESNE C, ROY P, WANG Z et aL: From peptidic to potent non-peptidic PTP1B inhibitors. Bioorg. Med. Chem. Lett. (2004) (In press).
   Google Scholar
• SHEN K, KENG Y-F, WU L, GUO X-L, LAWRENCE DS, ZHANG Z-Y: Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J. Biol. Chem. (2001) 276:47311–47319.
   PubMed Web of Science ®Google Scholar
• GUO X-L, SHEN K, WANG F, LAWRENCE DS, ZHANG Z-Y: Probing the molecular basis for potent and selective PTP1B inhibition. J. Biol. Chem. (2002) 277:41014–41022.
   PubMed Web of Science ®Google Scholar
• SUN JP, FEDOROV AA, LEE SY et al.: Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. Biol. Chem. (2003) 278:12406–12414.
   Web of Science ®Google Scholar
• TAYLOR SD, KOTORIS CC, DINAUT AN, WANG Q, RAMACHANDRAN C, HUANG Z: Potent non-peptidyl inhibitors of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. (1998) 6:1457–1468.
   PubMed Web of Science ®Google Scholar
• JIA Z, YE Q, DINAUT A et al.: Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. J. Med. Chem. (2001) 44:4584–4594.
   PubMed Web of Science ®Google Scholar
• TAING M, KENG YF, SHEN K, WU L, LAWRENCE DS, ZHANG ZY: Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B. Biochemistry (1999) 38:3793–3803.
   PubMed Web of Science ®Google Scholar
• HUANG P, RAMPHAL J, WEI J et al.: Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases. Bioorg. Med. Chem. (2003) 11:1835–1849.
   PubMed Web of Science ®Google Scholar
• LAU CK, BAYLY C, GAUTHIER JY et cll.:Structure based design of a series of potent and selective non-peptidic PTP1B inhibitors. Bioorg. Med. Chem. Lett. (2004) (In press).
   Google Scholar
• SCAPIN G, PATEL SB, BECKER JW et al.: The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. Biochemistry (2003) 42:11451–11459.
   PubMed Web of Science ®Google Scholar
• IVERSEN LF, MOLLER KB, PEDERSEN AK et al.: Structure determination of T cell protein-tyrosine phosphatase. J. Biol. Chem. (2002) 277:19982–19990.
   PubMed Web of Science ®Google Scholar
• YOU-TEN KE, MUISE ES, ITIE A et al.:Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. (1997) 186:683–963.
   PubMed Web of Science ®Google Scholar
• LIU G, SZCZEPANKIEWICZ BG, PEI Z et al.: Discovery and structure-activity relationship of oxalylarylarninobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. (2003) 46:2093–2103.
   PubMed Web of Science ®Google Scholar
• XIN Z, OOST TK, ABAD-ZAPATERO C et al.: Potent, selective inhibitors of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett. (2003) 13:1887–1890.
   PubMed Web of Science ®Google Scholar
• SZCZEPANKIEWICZ BG, LIU G, HAJDUK PJ et al.: Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am. Chem. Soc. (2003) 125:4087–4096.
   PubMed Web of Science ®Google Scholar
• LIU G, XIN Z, LIANG H et al.: Selectiveprotein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands: J Med. Chem. (2003) 46:3437–3440.
   Google Scholar
• PEI Z, LI X, LIU G et al.: Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:3129–3132.
   PubMed Web of Science ®Google Scholar
• XIN Z, LIU G, ABAD-ZAPATERO C et al.: Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett. (2003) 13:3947–3950.
   PubMed Web of Science ®Google Scholar
• LIU G, XIN Z, PEI Z et al.: Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J Med. Chem. (2003) 46:4232–4235.
   PubMed Web of Science ®Google Scholar
• ANDERSEN HS, IVERSEN LF, JEPPESEN CB et al.: 2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J Biol. Chem. (2000) 275:7101–7108.
   PubMed Web of Science ®Google Scholar
• IVERSON LF, ANDERSON HS, MOLLER KB et al.: Steric hindrance as a basis for the structure-based design of selective inhibitors of protein tyrosine phosphatases. Biochemistry (2001) 40:14812–14820.
   PubMed Web of Science ®Google Scholar
• IVERSON LF, ANDERSON HS, BRANNER S et al.: Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J Biol. Chem. (2000) 275:10300–10307.
   PubMed Web of Science ®Google Scholar
• ANDERSEN HS, OLSEN OH, IVERSEN LF et al.: Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein tyrosine phosphatase. J. Med. Chem. (2002) 45:4443–4459.
   PubMed Web of Science ®Google Scholar
• LIU DG, GAO Y, VOIGT JH et al.: Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration. Bioorg. Med. Chem. Lett. (2003) 13:3005–3007.
   PubMed Web of Science ®Google Scholar
• WROBEL J, SREDY J, MOXHAM C et al.: PTP1B inhibition and antihyperglycemic activity in the °blob mouse model of novel 11-arylbenzo [b] naphtho [2,3-d] furans and11-arylbenzo [b] naphtho [2,3-d] thiophenes. J. Med. Chem. (1999) 42:3199–3202.
   PubMed Web of Science ®Google Scholar
• MALAMAS MS, SREDY J, MOXHAM C et al.: Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties.J. Med. Chem. (2000) 43:1293–1310.
   Google Scholar
• WROBEL J, LIZ, SREDY J, SAWICKI DR, SEESTALLER L, SULLIVAN D: Synthesis and PTP1B Inhibition of Novel 4-Aryl-1-Oxa-9-Thiacyclopenta[B]fluorenes. Bioorg. Med. Chem. Lett. (2000) 10:1535–1538.
   PubMed Web of Science ®Google Scholar
• BURKEY B, DONG M, WENOGLE L et al.: Pharmacogenomic evaluation of a putative orally active PTP1B inhibitor using °blob mice reveals an alternative mechanism of action. Diabetes (2002) 51\(Suppl. 2):138-0R.
   Google Scholar
• MALAMAS MS, SREDY J, GUNAWAN I et al.: New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties.J. Med. Chem. (2000) 43:995–1010.
   Google Scholar
• MALAMAS MS, SREDY J, MOXHAM C et al.: Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties.J. Med. Chem. (2000) 43:1293–1310.
   Google Scholar
• GUERTIN KR, SETTI L, QI L et al.: Identification of a novel class of orally active pyrimido [5,4-3] [1,2,4] triazine-5,7-diarnine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity. Bioorg. Med. Chem. Lett. (2003) 13:2895–2898.
   PubMed Web of Science ®Google Scholar
• SHIM YS, KIM KC, CHI DY, LEE KH, CHO H: Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:2561–2563.
   PubMed Web of Science ®Google Scholar
• BLEASDALE JE, OGG D, PALAZUK BJ et al.: Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry (2001) 40:5642–5654.
   PubMed Web of Science ®Google Scholar
• LARSEN SD, BARF T, LILJEBRIS C et al.:Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. J Med. Chem. (2002) 45:598–622.
   PubMed Web of Science ®Google Scholar
• LILJEBRIS C, LARSEN SD, OGG D, PALAZUK BJ, BLEASDALE JE: Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity. J. Med. Chem. (2002) 45:1785–1798.
   PubMed Web of Science ®Google Scholar
• LARSEN SD, STEVENS FC, LINDBERG TJ et al.: Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: identification of analogues with cellular activity. Bioorg. Med. Chem. Lett. (2003) 13:971–975.
   PubMed Web of Science ®Google Scholar
• LILJEBRIS C, MARTINSSON J, TEDENBORG Let al.: Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B). Bioorg. Med. Chem. (2002) 10:3197–3212.
   Google Scholar
• XIE L, LEE SY, ANDERSEN JN et al.: Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemist?), (2003) 42:12792–12804.
   PubMed Web of Science ®Google Scholar
• •Although the data in [86] suggests that compound 45 and PTP1B colocalise in the ER, no control experiment was run using a compound with similar hydrophobic properties that was not a PTP1B inhibitor. It is very possible that such a compound would also localise in the same regions of the cell.
   Google Scholar
• ZINKER BA, RONDINONE CM, TREVILLYAN JM et al.: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA (2002) 99:11357–11362.
   PubMed Web of Science ®Google Scholar
• ••This report and references [88-90] describe some of the effects of a PTP1B ASO on glucose and fat metabolism.
   Google Scholar
• GUM RJ, GAEDE LL, KOTERSKI SL et al.: Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes (2003) 52:21–28.
   PubMed Web of Science ®Google Scholar
• RONDINONE CM, TREVILLYAN JM, CLAMPIT Jet al.: Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes (2002) 51:2405–2411.
   Google Scholar
• WARING JF, CIURLIONIS R, CLAMPIT JE et al.: PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat. Mal Cell Endocrinol (2003) 203:155–168.
   PubMed Web of Science ®Google Scholar